Palogic Value Management L.P. bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT – Free Report) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 4,922,442 shares of the company’s stock, valued at approximately $9,796,000. Health Catalyst accounts for approximately 3.2% of Palogic Value Management L.P.’s holdings, making the stock its 5th largest holding. Palogic Value Management L.P. owned approximately 0.07% of Health Catalyst as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in HCAT. Bank of America Corp DE bought a new stake in shares of Health Catalyst in the second quarter worth $104,000. Hsbc Holdings PLC acquired a new position in Health Catalyst during the 2nd quarter worth $809,000. Canada Pension Plan Investment Board bought a new stake in shares of Health Catalyst in the 2nd quarter worth about $134,000. Visionary Wealth Advisors acquired a new stake in shares of Health Catalyst in the 2nd quarter valued at about $27,000. Finally, EP Wealth Advisors LLC bought a new position in shares of Health Catalyst during the second quarter worth about $99,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.
Health Catalyst Stock Performance
Shares of HCAT opened at $1.59 on Thursday. Health Catalyst, Inc. has a 1 year low of $0.96 and a 1 year high of $3.80. The company has a market cap of $119.66 million, a price-to-earnings ratio of -0.43 and a beta of 1.55. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.70 and a current ratio of 2.70. The firm has a fifty day moving average of $1.98 and a 200-day moving average of $1.66.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Canaccord Genuity Group restated a “hold” rating and set a $1.80 price objective (down from $3.00) on shares of Health Catalyst in a research note on Thursday, August 20th. Wells Fargo & Company lowered their price target on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a report on Thursday, August 13th. Citigroup dropped their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Stephens decreased their price objective on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Health Catalyst in a research note on Monday, May 11th. Three research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.71.
Check Out Our Latest Research Report on HCAT
Health Catalyst Profile
Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.
The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.
Read More
- Five stocks we like better than Health Catalyst
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT – Free Report).
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
